Overview

* Olema Q2 net loss widens to $43.8 mln from $30.4 mln last year

* Cash and marketable securities total $361.9 mln, down from $434.1 mln last year

* Co to report OPERA-01 top-line data in H2 2026, OPERA-02 to start Q3 2025

* Q2 with $361.9 mlEnded n in cash, supporting ongoing and future clinical development activities

*

Outlook

* Company expects OPERA-01 top-line data in H2 2026

* Olema to initiate OPERA-02 trial in Q3 2025

* Company plans to present Phase 1b/2 data at ESMO 2025

* Initial clinical results for OP-3136 expected in 2026

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$43.78

Income mln

Q2 Basic -$0.51

EPS

Q2 -$47.86

Income mln

From

Operatio

ns

Q2 $47.86

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Olema Pharmaceuticals Inc ( OLMA ) is $24.50, about 81.1% above its August 8 closing price of $4.64

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)